TLDR
Morgan Stanleys E*TRADE brokerage has completed its rollout of spot trading for Bitcoin (BTC), Ethereum (ETH), and Solana (SOL) to eligible retail clients in the US.
- E*TRADE now offers 24/7 spot BTC, ETH, and SOL trading in its standard brokerage interface, with custody handled by Zerohash and fees of about 0.50 percent per trade.
- Millions of traditional brokerage users can access these three coins without using a separate crypto exchange, deepening mainstream adoption and potentially boosting demand, especially for Solana.
- Next steps include enabling crypto transfers, moving custody to a dedicated digital asset bank, and launching ETH and SOL ETFs, all against a changing US regulatory backdrop.
Deep Dive
1. Service Details And Limitations
Reports confirm ETRADE has finished a nationwide rollout allowing eligible US clients to buy, sell, and hold BTC, ETH, and SOL directly in the same interface they use for stocks and ETFs, with trading available 24/7 on web and mobile apps. The service is powered by Zerohash, which provides execution, liquidity, custody, and settlement, holding digital assets in linked accounts rather than on ETRADEs own balance sheet. The platform charges a 50 basis point fee per transaction, undercutting some competing retail venues, according to a detailed overview of the completed rollout.
At launch, crypto positions do not carry FDIC or SIPC protections like traditional cash or securities, and external transfers of coins into or out of E*TRADE accounts are planned for later in 2026 rather than being available immediately. Eligibility, risk disclosures, and limits are handled through the brokerages existing compliance framework.
2. Why BTC, ETH And SOL Access Matters
By integrating spot crypto trading into a mainstream brokerage that already serves millions of retail accounts, Morgan Stanley is lowering friction for first-time exposure to BTC, ETH, and SOL. Users can now view these positions alongside equities and ETFs rather than opening accounts at separate exchanges, a shift highlighted in coverage of E*TRADEs new crypto feature for retail investors.
Because the service focuses on direct spot coins rather than only ETFs or futures, it adds a new on-ramp to the underlying assets themselves. Several analyses note that Solanas inclusion, alongside Bitcoin and Ethereum, could support incremental demand for SOL as a third pillar asset in traditional channels.
If you already use E*TRADE, crypto becomes another asset class in your existing dashboard, making it easier to add or trim BTC, ETH, or SOL within a familiar workflow, but with distinct risk and protection rules.
3. What To Watch Next
The rollout is part of a broader Morgan Stanley digital asset strategy that includes a spot Bitcoin ETF, amended registration filings for Ethereum and Solana ETFs, and an application for a national trust bank charter focused on crypto custody via Morgan Stanley Digital Trust, as described in a strategy overview.
Key upcoming milestones to watch are:
- Activation of crypto transfer functionality, which would let clients move BTC, ETH, and SOL on and off the platform.
- Launch timing and structure of planned ETH and SOL ETFs, which would add fund-based exposure alongside direct coins.
- US regulatory developments such as the CLARITY Act, which could reshape oversight of spot digital commodities and influence how banks scale these services.
Confidence: high because multiple independent news outlets and Morgan Stanley communications report consistent details on assets, fees, custody, and roadmap.
Conclusion
E*TRADEs move to offer spot BTC, ETH, and SOL inside a mainstream brokerage account is a clear step in the convergence of traditional finance and crypto, putting top coins alongside stocks for everyday investors. The immediate impact is easier access and a new retail funnel, while the next wave will depend on whether transfers, dedicated custody, and new ETFs arrive smoothly under evolving regulation. For crypto users, the signal is that large brokers are treating BTC, ETH, and SOL as core asset options rather than experimental side products.
